-
Lorcaserin submitted for FDA review, FDA advisory panel votes against phentermine/topiramate, mixed vote on rosiglitazone, advisory panel votes to remove breast cancer indication from bevacizumab labeling, no increase in seizures found with DTaP vaccine, new REMS for quinine.
-
-
Current guidelines recommend mitral-valve surgery for severe organic mitral regurgitation in asymptomatic patients if exercise pulmonary hypertension (PASP > 60 mmHg) is demonstrated.
-
The dispatcher-assisted resuscitation trial (DART) tested the hypothesis that 911 dispatcher instructions to provide chest compressions only would be superior to similar instructions that included both chest compressions and rescue breathing.
-
There is considerable concern regarding in-stent thrombosis of drug-eluting stents (DES) when aspirin and clopidogrel are stopped for non-cardiac surgery (NCS), but a paucity of data.
-
Although ischemic left ventricular (LV) dysfunction is an indication for revascularization, little is known about the long-term benefits of revascularization and the value of viability studies.
-
WHO recommendations for antiviral use for H1N1 flu; antibiotic use trends for acute respiratory tract infection; denosumab clears FDA Expert Panel; FDA Actions.
-
A retrospective study of 12,333 infants < 6 months of age with urinary tract infections showed no difference in treatment failure between short-course (≤ 3 days) and long-course (≥ 4 days) of antibiotic therapy.
-
In this single-center study of what happened to 126 consecutive patients who survived an ICU admission requiring prolonged mechanical ventilation, 56% of them were alive after one year, but only 11 of these were functioning independently. On average, the patients spent 74% of all post-discharge days in the hospital, in a post-acute care facility, or at home receiving paid home health care.
-
Lorcaserin submitted for FDA review, FDA advisory panel votes against phentermine/topiramate, mixed vote on rosiglitazone, advisory panel votes to remove breast cancer indication from bevacizumab labeling, no increase in seizuress